Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.

Only a limited number of target molecules have been shown to be recognized by colon tumor-reactive T cells, limiting the options for the development of immunotherapies for patients with colon cancer. The current studies were undertaken in an attempt to generate tumor-reactive T cells that could be used to identify and characterize novel colon tumor-associated antigens. Multiple CD4(+) T-cell clones isolated either from tumor-infiltrating lymphocytes or peripheral blood mononuclear cells that were sensitized in vitro with autologous tumor cells from a colon cancer patient, 1869, recognized autologous tumor cells in a class II HLA-DR-restricted manner. One of the peripheral blood mononuclear cell clones, clone C111, was used to screen pools of clones that were generated from an autologous colon tumor cell line cDNA library. A cDNA clone that was isolated encoded a protein that was termed colorectal tumor-associated antigen-1 (COA-1). This product was recognized in the context of the two autologous HLA-DRbeta1 alleles, HLA-DRbeta1*0402 and DRbeta1*1301. The nucleotide sequence of the COA-1 transcript was nearly identical to multiple expressed sequence tag sequences that encode variants of Socius, a protein that was found recently to bind to members of the Rnd family of GTPases. The COA-1 gene was expressed at relatively comparable levels in colorectal and melanoma tumor cells, EBV-infected B cells, normal B cells, and cultured fibroblast cell lines. However, the gene that was isolated from normal cell types contained a single nucleotide substitution, resulting in an amino acid change near the COOH terminus of the protein. Although the minimal epitope recognized by CD4(+) cells was encoded by sequences that were upstream from this substitution, C111 T cells did not appear to recognize the normal gene product. Therefore, this alteration may either affect the localization or the processing of this gene product, which may at least in part be responsible for the differential recognition of tumor and normal cells.

[1]  S. Rosenberg,et al.  Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma , 2002, The Journal of Immunology.

[2]  K. Mori,et al.  Socius Is a Novel Rnd GTPase-Interacting Protein Involved in Disassembly of Actin Stress Fibers , 2002, Molecular and Cellular Biology.

[3]  J. Nesland,et al.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Shichijo,et al.  Molecular basis of T cell-mediated recognition of pancreatic cancer cells. , 2001, Cancer research.

[5]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[6]  P. Kuppen,et al.  T cell responses in colorectal cancer patients: Evidence for class II HLA‐restricted recognition of shared tumor‐associated antigens , 2000, International journal of cancer.

[7]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[8]  K. Shirouzu,et al.  Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. , 1999, Cancer research.

[9]  S. Rosenberg,et al.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.

[10]  D. Harrington The tea leaves of small trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Hanna,et al.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[12]  T. Lybrand,et al.  Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. , 1998, Journal of immunology.

[13]  M. Ogawa,et al.  Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus , 1998, Cancer Immunology, Immunotherapy.

[14]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[15]  K. Haruma,et al.  Combined Expression of HLA-DR Antigen and Proliferating Cell Nuclear Antigen Correlate with Colorectal Cancer Prognosis , 1998, Oncology.

[16]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[18]  J. Schlom,et al.  Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Olivier,et al.  Tyrosine kinase and cAMP‐dependent protein kinase activities in CD40‐activated human B lymphocytes , 1996, European journal of immunology.

[20]  J. Turnay,et al.  Characterization of tumorigenic sub‐lines from a poorly tumorigenic human colon‐adenocarcinoma cell line , 1996, International journal of cancer.

[21]  J. Bodmer,et al.  Mechanisms of loss of HLA class I expression on colorectal tumor cells. , 1996, Tissue antigens.

[22]  A. Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[23]  E. Appella,et al.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.

[24]  N. Chakraborty,et al.  Immunobiology and immunotherapy of melanoma , 1995, Current opinion in oncology.

[25]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[26]  P. Mingazzini,et al.  The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. , 1992, International surgery.

[27]  M. Hanna,et al.  Expression of class II major histocompatibility complex molecules correlates with human colon tumor vaccine efficacy. , 1992, Cancer research.

[28]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[29]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[30]  P. Coulie,et al.  Antitumor immunity at work in a melanoma patient. , 1999, Advances in cancer research.

[31]  E. Appella,et al.  A Mutated f3-Catenin Gene Encodes a Melanoma-specifi c Antigen Recognized by Tumor Infiltrating Lymphocytes By Paul F. tLobbins,* Mona E1-Gamil,* Yong F. Li,* , 1996 .

[32]  J. Jacobson,et al.  Colorectal cancer: Detection, treatment, and rehabilitation , 1994, CA: a cancer journal for clinicians.